On March 4th, Hong Kong-listed pharmaceutical giant Sino Biopharmaceutical (01177.HK) and global pharmaceutical giant Sanofi jointly announced an exclusive global licensing agreement for rovaxitinib, a first-in-class JAK/ROCK dual-target inhibitor.
According to the agreement, Sino Biopharmaceutical and its subsidiary, Chia Tai Tianqing Pharmaceutical Group, will grant Sanofi exclusive rights to develop, manufacture, and commercialize the product globally. Sino Biopharmaceutical will also receive an upfront payment of US$135 million, potential development, regulatory, and sales milestone payments of up to US$1.395 billion, and a double-digit percentage of sales royalties. This is the largest licensing transaction ever undertaken by a Chinese pharmaceutical company in the transplantation field.
This is not only Sino Biopharmaceutical's first innovative drug licensing project with a multinational pharmaceutical company (MNC) in recent years, but also a rare instance of a Chinese Big Pharma company reaching a full-equity licensing collaboration with a global MNC for mature late-stage clinical assets.
Xie Qirun, Chairman of the Board of Directors of Sino Biopharmaceutical, stated, “We are delighted to partner with Sanofi to bring our first-in-class JAK/ROCK inhibitor to patients worldwide. This collaboration marks a significant milestone in our global expansion strategy, and Sino Biopharmaceutical remains committed to becoming the preferred Chinese partner for multinational pharmaceutical companies. We firmly believe that by leveraging Sanofi's global R&D and commercialization advantages, we will further accelerate the rollout of innovative products, bringing more breakthrough therapies to patients globally.”
Rovaxitinib's groundbreaking clinical value is considered a key factor in facilitating this global collaboration.
As a first-in-class drug independently developed by Chia Tai Tianqing Pharmaceutical Group, rovaxitinib is the world's first small molecule inhibitor targeting both JAK and ROCK. Through synergistic action along two pathways, it achieves dual pharmacological effects of anti-inflammation and anti-fibrosis, precisely targeting the core pathological mechanisms of diseases such as myeloproliferative neoplasms and transplant rejection. It is a benchmark product globally with leading development progress and impressive clinical data among drugs targeting the same target.
The product currently has two core indications: myelofibrosis (MF) and GVHD (graft-versus-host disease). Myelofibrosis (MF) was included in China's second batch of rare disease catalogs in 2023, with over 60,000 new cases annually and over 200,000 existing patients. Rovaxitinib, with its dual-target mechanism, has achieved breakthroughs in both efficacy and safety. Phase III clinical data show significantly improved spleen-shrinking effects and symptom improvement rates, and a substantial reduction in the incidence of adverse reactions. In February 2026, rovaxitinib (trade name: Anxu®) was approved for marketing by the National Medical Products Administration (NMPA) of China for first-line treatment of adult patients with intermediate-2 or high-risk primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-thrombocythemia vera myelofibrosis (PET-MF).
The breakthrough potential in GVHD has further enhanced rovaxitinib's global recognition. In February 2025, the results of a Phase Ib/IIa study of rovaxitinib for cGVHD were published in the top hematology journal *Blood*. Data showed that 59.1% of subjects experienced significant improvement in rejection symptoms, with an optimal overall response rate of 86.4%; the 12-month failure-free survival rate reached 85.2%, significantly superior to approved therapies, and exhibiting excellent safety and tolerability. Currently, this indication has been included in China's CDE (Center for Drug Evaluation) for Breakthrough Therapy designation, with domestic Phase III clinical trials progressing steadily. Simultaneously, it has received FDA approval in the United States to conduct Phase II clinical trials, fully initiating its global development process.
Since last year, there has been a surge in the overseas licensing of innovative Chinese drugs, but most of these are early-stage assets. This transaction between Sino Biopharmaceutical and Sanofi is not only one of the most significant innovative drug business developments since the beginning of 2026, but also a rare overseas licensing transaction targeting late-stage clinical assets.
Industry insiders believe that this signifies that leading domestic pharmaceutical companies, represented by China Biopharmaceutical, have received rigorous system certification from top global pharmaceutical companies for their full-chain R&D capabilities, from drug initiation, clinical development, registration application to production quality control. It also means that this leading Chinese pharmaceutical company has further improved its two-way business development capability loop from "bringing in" to "going out," opening up space for the global value release of its vast innovation pipeline matrix.
For Sanofi, a leading multinational pharmaceutical company deeply rooted in vaccines, autoimmune diseases, and rare diseases, transplantation is a core strategic area. Rovaxitinib's breakthrough clinical value in cGVHD aligns perfectly with Sanofi's pipeline; moreover, this late-stage clinical mature asset carries low development risk and can quickly supplement Sanofi's product portfolio in transplantation and hematological diseases, consolidating its global market position.
In China's innovative drug industry, business development (BD) capabilities are a comprehensive reflection of a company's R&D strength, commercialization capabilities, and global vision. Previously, Sino Biopharmaceutical, leveraging its strong local commercialization capabilities and full-chain clinical development strength, became one of the core strategic partners of top global MNCs such as Boehringer Ingelheim in China. The significant transaction with Sanofi serves as authoritative endorsement that Sino Biopharmaceutical's self-developed full-chain capabilities meet international standards, completely opening up global valuation potential for the company's subsequent innovative pipeline.
In recent years, Sino Biopharmaceutical has continuously expanded its innovative pipeline matrix through a dual-engine approach of internal R&D and external mergers and acquisitions, accumulating ample "ammunition" for its overseas BD efforts. In particular, through acquisitions of emerging innovative pharmaceutical companies such as Lixin Pharmaceuticals and Hergia Biotech, coupled with its own independent R&D system built up over two decades of continuous investment, Sino Biopharmaceutical has accumulated a vast innovative pipeline matrix covering multiple core areas including oncology, liver disease, respiratory, and cardiovascular metabolism, and has reserved a large number of FIC and BIC assets with global development potential.
This year, Sino Biopharmaceutical will release significant clinical data at several top global academic conferences, including TQH3906 (TYK2 inhibitor), LM/302 (CLDN18.2 ADC), LM/108 (CCR8 monoclonal antibody), TQB3019 (BTK OAPD), Kylo-11 (LPA), etc., laying a solid foundation for external licensing and cooperation.
With the completion of the rovaxitinib transaction, Sino Biopharmaceutical's external licensing capabilities have received a crucial validation. Its vast innovative drug pipeline assets are also expected to accelerate its global expansion through business development, opening up a second growth curve for the company's internationalization.
